Merck & Co., Inc. vs Super Micro Computer Inc — how do they compare? Merck & Co., Inc. trades at $146.07 (market cap $351.28B), while Super Micro Computer Inc trades at $41.6 (market cap $28.10B). The key difference: Merck & Co., Inc. is far larger — about 12.5× Super Micro Computer Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Super Micro Computer Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Super Micro Computer Inc for 19 Days on average.
| MRK | SMCI | |
|---|---|---|
Market Cap | $351.28B | $28.10B |
Volume | 7,969,665 | 38,581,805 |
Sector | Health | Technology |
52-Week High | $156.43 | $57.98 |
52-Week Low | $82.49 | $20.53 |
Typical Hold Time | 98 Days | 19 Days |
Enterprise Value | $398.04B | $33.56B |
Dividend Yield | 2.39% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Super Micro Computer (SMCI) trades at $41.34, down 8.03% in the last session, but maintains strong fundamental performance with consistent earnings beats and robust revenue growth projections. The stock shows bullish technical signals with support at $40 and resistance at $44, while valuation metrics remain attractive with a P/E of 13.12 and P/S of 0.76. Recent news highlights AI server demand growth and new NVIDIA Vera Rubin platform shipments.
SMCI presents a compelling value opportunity with strong AI-driven growth prospects, though investors face risks from competitive pressures and potential regulatory scrutiny. Analyst consensus leans neutral with a $42.33 price target, while institutional interest remains strong given the company's positioning in the expanding AI infrastructure market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →